SCM
PCRX icon

Spyglass Capital Management’s Pacira BioSciences PCRX Stock Holding History

Spyglass Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-831,037
Closed -$33.9M – 27
2023
Q1 		$33.9M Sell
831,037
-37,649
-4% -$1.5M 2.56% 23
2022
Q4 		$33.5M Sell
868,686
-383,656
-31% -$18.7M 2.69% 21
2022
Q3 		$66.6M Sell
1,252,342
-208,292
-14% -$11.6M 4.71% 8
2022
Q2 		$85.2M Sell
1,460,634
-410,406
-22% -$26.9M 4.73% 10
2022
Q1 		$143M Sell
1,871,040
-232,125
-11% -$15.5M 4.88% 7
2021
Q4 		$127M Sell
2,103,165
-108,045
-5% -$5.96M 3.36% 18
2021
Q3 		$124M Buy
2,211,210
+93,537
+4% +$5.39M 2.84% 23
2021
Q2 		$129M Buy
2,117,673
+139,776
+7% +$8.85M 2.86% 19
2021
Q1 		$139M Buy
1,977,897
+5,327
+0.3% +$381K 3.65% 16
2020
Q4 		$118M Buy
1,972,570
+159,693
+9% +$9.35M 3.62% 16
2020
Q3 		$109M Buy
1,812,877
+282,046
+18% +$16.4M 5.04% 7
2020
Q2 		$80.3M Buy
1,530,831
+340,294
+29% +$14.2M 4.97% 6
2020
Q1 		$39.9M Buy
1,190,537
+333,710
+39% +$13.9M 4.51% 10
2019
Q4 		$38.8M Buy
856,827
+399,577
+87% +$17M 4.98% 5
2019
Q3 		$17.4M Buy
457,250
+77,641
+20% +$3.1M 4.62% 9
2019
Q2 		$16.5M Buy
379,609
+141,282
+59% +$6M 5.22% 5
2019
Q1 		$9.07M Buy
238,327
+118,170
+98% +$4.61M 3.51% 17
2018
Q4 		$5.17M Buy
+120,157
New +$5.61M 3.87% 17

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Spyglass Capital Management's PCRX Position: Q2 2023 in Review

Spyglass Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 831,037 shares — an estimated $33.9M sold.

Spyglass Capital Management first reported a position in PCRX in Q4 2018 and held it in 18 quarters. The position peaked at $143M in Q1 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

  • Spyglass Capital Management reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
  • Spyglass Capital Management sold 831,037 Pacira BioSciences shares in Q2 2023, an estimated $33.9M.
  • Spyglass Capital Management first reported a position in Pacira BioSciences in Q4 2018 and held it in 18 quarters.
  • Spyglass Capital Management's Pacira BioSciences position peaked at $143M in Q1 2022.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Spyglass Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.